Understanding the Importance of Bioresearch Monitoring Information in Regulatory Submission Readiness
When a biotech or pharmaceutical company is preparing for an NDA or BLA submission, the focus naturally turns to clinical, nonclinical, CMC, statistical, and administrative content.
But there is another critical component that can significantly affect FDA's ability to evaluate the integrity of the clinical data supporting the application: Bioresearch Monitoring, or BIMO.
For regulatory operations teams, BIMO should not be treated as an activity that begins after an NDA or BLA is submitted. It should be considered part of the submission planning and inspection-readiness process throughout clinical development.
FDA's BIMO Program is designed to monitor the conduct and reporting of FDA-regulated research. Its objectives include protecting research participants and assuring the quality and integrity of data submitted to support new product approvals and marketing applications.
What Is BIMO?
BIMO stands for Bioresearch Monitoring.
FDA describes BIMO as a comprehensive program involving inspections, data audits, and regulatory assessments designed to monitor FDA-regulated research.
The program covers multiple areas, including:
Clinical investigators
Sponsors
Contract Research Organizations (CROs)
Clinical trial monitors
Institutional Review Boards (IRBs)
Nonclinical laboratories
Bioequivalence facilities
Postmarketing activities
The program operates both domestically and internationally and supports FDA's evaluation of the quality and integrity of data used in regulatory decision-making.
What Is a BIMO Package?
The term “BIMO package” is commonly used within regulatory operations to describe the information and standardized data submitted to FDA to support BIMO inspection planning and execution.
For CDER-regulated NDAs and BLAs, FDA's final guidance, Standardized Format for Electronic Submission of NDA and BLA Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for CDER Submissions, establishes standardized electronic submission requirements for information from major clinical studies supporting the application.
The information allows FDA to identify clinical sites and other entities that may need inspection and provides FDA investigators with information needed to conduct those inspections. The BIMO submission can include information at several levels, including:
Study-Level Information
This provides FDA with information about the clinical study itself.
Examples include information associated with:
Study identification
Study design
Study population
Study status
Investigational product
Study dates
Major study characteristics
Site-Level Information
Site-level information helps FDA understand where the clinical research was conducted.
This can include information about:
Clinical sites
Investigators
Site locations
Enrollment
Site-specific study information
Subject-Level Information
Subject-level information provides additional detail that FDA can use to evaluate and prioritize potential inspection sites.
The BIMO Technical Conformance Guide provides FDA's current specifications and recommendations for preparing and submitting Clinical Study-Level Information, Subject-Level Data Line Listings by Clinical Site, and a Summary-Level Clinical Site Dataset.
How Does BIMO Fit Into an NDA or BLA?
This is where BIMO becomes particularly important for regulatory operations.
An NDA or BLA is not simply a collection of clinical study reports.
FDA needs to evaluate not only what the clinical studies found, but also whether the studies were conducted appropriately and whether the underlying data are reliable.
Think of the relationship this way:
Clinical Trial → Clinical Data → Clinical Study Report → NDA/BLA
But alongside that pathway is:
Clinical Trial → BIMO Information → FDA Inspection Planning → Inspection/Assessment → Confidence in Data Integrity
BIMO therefore provides an important connection between clinical development and FDA's inspection program.
BIMO and the NDA/BLA Submission Timeline
One of the biggest misconceptions is that BIMO preparation begins when the marketing application is submitted.
For regulatory operations teams, that is too late.
BIMO information is generated from clinical development activities that occur months or years before filing. That means BIMO readiness should be incorporated into the overall regulatory submission plan.
Early Development
During clinical development, sponsors should establish processes for capturing and maintaining information that may ultimately be required for BIMO submission and inspection readiness.
Late-Stage Development
As pivotal studies progress, teams should begin validating:
Site information
Investigator information
Enrollment information
Study data
Site-level information
Data listings
Study documentation
CRO information
Clinical trial records
Pre-NDA/BLA
The regulatory operations team should begin assembling and reviewing the BIMO information well before the anticipated filing date.
This is where the regulatory content planner becomes extremely valuable.
NDA/BLA Submission
The applicable BIMO information is submitted in the standardized electronic format required by FDA. FDA then uses the information to assist with BIMO inspection planning.
What Does a Regulatory Operations Team Need to Manage?
BIMO is a perfect example of why regulatory operations is much more than publishing documents.
A regulatory operations team may need to coordinate information from:
Clinical Operations
→ Sites→ Investigators→ Enrollment→ Study conduct
Data Management
→ Subject-level information→ Data listings→ Data reconciliation
Clinical
→ Study information→ Clinical Study Reports→ Protocol information
Regulatory
→ Submission strategy→ Application content→ FDA requirements
CROs/Vendors
→ Site information→ Investigator information→ Trial documentation
Regulatory Operations
→ Data collection→ Quality checks→ Formatting→ Technical validation→ Submission readiness→ Final publishing
This makes BIMO a cross-functional submission activity, not simply a clinical operations responsibility.
Why BIMO Should Be Part of Your Regulatory Submission Content Planner
This is perhaps the biggest takeaway for emerging biotech companies.
A regulatory submission content planner should not only track the obvious documents such as:
Clinical Study Reports
Investigator's Brochures
Protocols
Statistical Analysis Plans
CMC documents
Nonclinical reports
Labeling
Summaries
It should also identify supporting regulatory information required for FDA review and inspection planning.
BIMO belongs on that roadmap.
A well-designed content planner can identify:
BIMO Activity | Owner | Dependency | QC | Target Date |
Study-level information | Clinical/Reg Ops | Final study data | Yes | TBD |
Site-level information | Clinical Ops | Site reconciliation | Yes | TBD |
Subject-level listings | Data Management | Database/data extracts | Yes | TBD |
BIMO dataset preparation | Data/Reg Ops | Source information | Yes | TBD |
Technical validation | Reg Ops/Publishing | Final datasets | Yes | TBD |
Final BIMO package | Regulatory Operations | QC completion | Yes | TBD |
NDA/BLA submission | Regulatory | Complete submission | Final | TBD |
The exact responsibilities will vary by sponsor, but the principle is the same:
If it is required to support the submission, it should have an owner, a deadline, dependencies, and a quality-control process.
Final Takeaway
An FDA BIMO package is more than an inspection-related administrative requirement.
It is part of the infrastructure that allows FDA to plan inspections and evaluate the reliability and integrity of the clinical research supporting an NDA or BLA. For sponsors preparing a marketing application, BIMO should therefore be treated as a planned submission workstream, not a last-minute inspection activity. For regulatory operations teams, that means incorporating BIMO requirements into the submission content planner early, assigning clear ownership, establishing dependencies, reconciling data across functions, and building sufficient time for QC and technical validation. The goal is simple:
Don't wait for FDA to identify a problem with your clinical-trial information. Build inspection readiness into your submission strategy from the beginning.
For emerging biotech companies, proactive BIMO planning can provide greater visibility, reduce last-minute submission risk, and help ensure that the clinical evidence supporting the NDA or BLA is organized and ready for FDA review.
FDA Resources
The Sugar Water Operations Team Helping emerging biotech companies turn complex regulatory requirements into organized, submission-ready operations.
Contact SWOT at info@sugarwaterops.com for additional questions regarding submission readiness and assistance establishing a controlled process for proper planning and collecting data.